SLC5A2 and hydrops fetalis: Despite these differences, all trials used independent adjudication committees to enhance outcome validity. These findings are consistent with results seen for dapagliflozin, another SGLT2 inhibitor, which also demonstrated reduced heart failure hospitalizations and cardiovascular benefits in trials like DAPA-HF and DELIVER, supporting a potential class effect [22,23].